Table 2

Survival Analysis

All-Cause MortalityCardiovascular Mortality
HR (95% CI) per 1 SDp ValueHR (95% CI) per 1 SDp Value
Derivation cohort
 Univariate1.96 (1.63–2.35)<0.0011.94 (1.56–2.41)<0.001
 Multivariate
  Model 11.83 (1.52–2.22)<0.0011.80 (1.43–2.27)<0.001
  Model 21.62 (1.26–2.08)<0.0011.72 (1.27–2.32)<0.001
  Model 31.40 (1.06–1.86)0.0191.36 (0.96–1.93)0.083
Validation cohort
 Univariate1.68 (1.45–1.95)<0.0011.55 (1.30–1.84)<0.001
 Multivariate
  Model 11.60 (1.37–1.88)<0.0011.45 (1.20–1.74)<0.001
  Model 21.56 (1.30–1.87)<0.0011.39 (1.12–1.73)0.003
  Model 31.45 (1.19–1.77)<0.0011.26 (1.01–1.60)0.053

Univariate and multivariate Cox proportional hazard models were applied to assess the effect of soluble urokinase-type plasminogen activator receptor on survival of patients. The p values in bold indicate a value of <0.05.

CI = confidence interval; HR = hazard ratio.

  • Model 1 was adjusted for age and sex.

  • Model 2 was adjusted for Model 1 plus New York Heart Association functional classification, left ventricular ejection fraction, cause of chronic heart failure, systolic blood pressure, estimated glomerular filtration rate (MDRD), diabetes, atrial fibrillation, hypertension, chronic obstructive pulmonary disease, and active smoking.

  • Model 3 was adjusted for Model 2 plus N-terminal pro B-type natriuretic peptide, C-reactive protein, and soluble ST2 (derivation cohort).